Results 191 to 200 of about 39,064 (303)

Current Status of Biosimilar Growth Hormone

, 2009
Paul Saenger
openalex   +1 more source

Presently available biosimilars in hematology-oncology: G-CSF [PDF]

, 2012
Pere Gascón
openalex   +1 more source

An overview of insulin therapy for the non‐specialist

Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 3-15, July 2025.
Abstract Nearly all health professionals, whatever their practice or speciality, now have contact with a significant number of insulin‐using people with diabetes. People with type 1 diabetes are nearly universally managed on more complex insulin regimens, increasingly with complex support technology, and with some understanding of the concepts ...
Philip D. Home
wiley   +1 more source

How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products

, 2009
Nicolas Rossignol
openalex   +2 more sources

Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market? [PDF]

, 2012
Lisa S. Rotenstein, Nina A. Ran, Joseph P. Shivers, Mark Yarchoan, Kelly L. Close   +4 more
openalex   +1 more source

Current status and considerations on biosimilar in China [PDF]

, 2012
Junzhi Wang
openalex   +1 more source

Real world evidence of insulin and biosimilar insulin therapy—Opportunities to improve adherence, outcomes and cost‐effectiveness

Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 45-62, July 2025.
Abstract Insulin has been discovered for more than a century; however, its benefits to people with diabetes are yet to be fully realized due to barriers related to access, quality of care and costs. Insulin therapy remains the cornerstone of diabetes management. The multicausality of diabetes and its subtypes calls for comprehensive phenotyping and use
Aimin Yang, Jiazhou Yu, Johnny T. K. Cheung, Juliana C. N. Chan, Elaine Chow   +4 more
wiley   +1 more source

Biosimilars: what clinicians should know [PDF]

, 2012
Martina Weise, Marie-Christine Bielsky, Karen De Smet, Falk Ehmann, Niklas Ekman, Thijs J. Giezen, Iordanis Gravanis, Hans‐Karl Heim, Esa Heinonen, Kowid Ho, Alexandre Moreau, Gopalan Narayanan, Nanna Aaby Kruse, Gabriele Reichmann, Robin Thorpe, Leon van Aerts, Camille Vleminckx, Meenu Wadhwa, Christian K. Schneider   +18 more
openalex   +1 more source

The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 24-35, July 2025.
Abstract The health economic value of insulin is usually expressed within a cost‐effectiveness framework providing an estimated incremental cost per quality‐adjusted life year (QALY) gained. Insulin clinical trials adopt a treat‐to‐target design in which both intervention and control arms aim to achieve similar levels of glycaemic control thereby ...
Phil McEwan, Marc Evans
wiley   +1 more source

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? [PDF]

, 2012
J. B. Warren
openalex   +1 more source